Paper Review Records
All Paper Review Records
12 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
Thrombotic and Hemorrhagic Events in Myeloproliferative Neoplasms
Kari Brown; Douglas TremblayShow moreShow less
1. Hematology/Oncology Section, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, USAShow moreShow less
Approach to Patients with Multiple Myeloma after BCMA targeted Therapy
Hanne Marie Norseth; Rakesh Popat; Fredrik SchjesvoldShow moreShow less
1. Oslo University Hospital; 2. University of Oslo; 3. University College London Hospitals NHS Foundation TrustShow moreShow less
Impact of Germline DNA Repair Mutations on Clonal Hematopoiesis and Myeloid Neoplasm Development
Kateryna Fedorov; Leo Y. Luo; Alexander G. Bick; Michael R. SavonaShow moreShow less
1. Vanderbilt-Ingram Cancer Center, Nashville, US; 2. Division of Hematology and Oncology, Department of Medicine, Nashville, US; 3. Vanderbilt School of Medicine, Vanderbilt University Medical Center, Nashville, US; 4. Department of Radiation Oncology, Nashville, US; 5. Division of Genetic Medicine, Department of Medicine, Nashville, USShow moreShow less
Targeting RUNX1 Germline Variants: Agents Under Investigation
Saman Ghalamkari; Christopher N. Hahn; Amelia Lau; Hamish S. Scott; Claire C. Homan; Anna L. BrownShow moreShow less
1. Centre for Cancer Biology, SA Pathology, University of South Australia, Adelaide, Australia; 2. Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, Australia; 3. Adelaide Medical School, The University of Adelaide, Adelaide, AustraliaShow moreShow less
The Evolving Therapeutic Landscape of Richter Transformation
Henry Le; Grace Baek; Ivan Huang; Chloe Siu; Mazyar ShadmanShow moreShow less
1. Department of Pharmacy, Fred Hutchinson Cancer Center, Seattle, USA; 2. Department of Pharmacy, University of Washington Medical Center, Seattle, United States; 3. Department of Cellular Immunotherapy, Fred Hutchinson Cancer Center, Seattle, USA; 4. Division of Hematology and Oncology, University of Washington School of Medicine, Seattle, USAShow moreShow less
Transforming the Treatment of Acute Lymphoblastic Leukemia: the Role of Bispecific Antibodies, Antibody-Drug Conjugates, and CAR T-cell Therapy
Tala Najdi; Sarah Khanfour; Joe Chalhoub; Shereen Sakkal; Fadi G. Haddad; Hampig Raphael KourieShow moreShow less
1. Department of Hematology-Oncology, Hotel-Dieu de France University Hospital, Beirut, Lebanon; 2. Saint Joseph University of Beirut, Beirut, Lebanon; 3. Faculty of Medicine, University of Montreal, Quebec, Canada; 4. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USAShow moreShow less
FAQ
How long does Current Hematologic Malignancy Reports take to review a manuscript?
As of 2026-11-19, CrushSCI has 12 complete review records for Current Hematologic Malignancy Reports. The fastest paper went from submission to acceptance in 1 days (The Evolving Therapeutic Landscape of Richter Transformation, received 2025-11-02, accepted 2025-11-03); the slowest took 196 days. The average is 57.8 days and the median is 49 days. The fastest record has an unusually short interval; please check the original source.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
